[Back to Our Trials]
CONTACT-02: A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Go To Trial Homepage
For more information you may call clinical trials department directly at 732-390-7750 or email us at
astera.clinicaltrial@asterahealthcare.org
.